Umecrine Cognition is led by a group of people with extensive experience in drug development and commercialization, with prior leadership positions in the Astra corporation, Medivir, Biovitrum (currently Sobi), Karo Bio, as well as regulatory experience from the Swedish MPA.

The board consists of individuals with extensive international experience in creating shareholder value in life science companies by providing knowledge in professional drug and business development, not the least on the U.S. market. Additionally, the company collaborates with world-leading experts in medicine who advise on the design of the continued clinical development programs.